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Abstract: The 2020 Kidney Disease Outcome Quality Initiative (KDOQI) Clinical Practice Guideline
for Nutrition in chronic kidney disease (CKD) recommends protein restriction to patients affected
by CKD in stages 3 to 5 (not on dialysis), provided that they are metabolically stable, with the
goal to delay kidney failure (graded as evidence level 1A) and improve quality of life (graded as
evidence level 2C). Despite these strong statements, low protein diets (LPDs) are not prescribed
by many nephrologists worldwide. In this review, we challenge the view of protein restriction
as an “option” in the management of patients with CKD, and defend it as a core element of care.
We argue that LPDs need to be tailored and patient-centered to ensure adherence, efficacy, and safety.
Nephrologists, aligned with renal dietitians, may approach the implementation of LPDs similarly to
a drug prescription, considering its indications, contra-indications, mechanism of action, dosages,
unwanted side effects, and special warnings. Following this framework, we discuss herein the benefits
and potential harms of LPDs as a cornerstone in CKD management.
Keywords: low protein diet; chronic kidney disease; nutrition; dietary management
1. Introduction
The type and quality of the diet that a patient follows is not trivial; it is a cornerstone in the
management of many diseases, as it is the case of chronic kidney disease (CKD) [1]. The main goals
of nutritional therapy in CKD are to avoid the accumulation of molecules that can reach toxic levels,
because of impaired kidney elimination, to counterbalance the pro-catabolic milieu that characterizes
advanced CKD stages, to reduce the generation of nitrogen compounds, and thus the retention of
nitrogen waste products [2,3]. Dietary protein restriction can prevent and/or correct signs and symptoms
of kidney failure, delay the time to kidney replacement therapy, and, perhaps counter-intuitively,
prevent the development of protein–energy wasting (PEW) [4,5]. A low protein diet (LPD) may
offer further metabolic benefits, including a better control of phosphate balance (important for the
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bone-mineral disease linked to CKD), provision of a higher dietary alkaline load (which can counteract
metabolic acidosis), and potentially better control of other aspects or complications of progressive
CKD, such as dyslipidemia, proteinuria, and inflammation [6].
The rationale, safety, and efficacy of LPDs delaying the start of dialysis are supported by
various trials, leading to propose them with an evidence graded as 1A in the 2020 National Kidney
Foundation-Kidney Disease Outcome Quality Initiative (NKF-KDOQI) Clinical Practical Nutrition
Guideline [7]. However, LPD implementation is not widespread because of various fears and
misconceptions. One concern is that LPD may induce PEW [8,9], but neither observational studies [10,11]
nor randomized controlled trials [12] support such concern, within a well-planned and monitored low
protein regimen. Instead, PEW is most likely part of the natural history of uremia rather than a direct
complication of dietary restriction [13,14]. Conversely, careful nutritional assessment and wise and
adapted dietary prescriptions, supplying enough energy to cover needs, may prevent PEW since LPDs
can reduce intoxication and correct several metabolic abnormalities and symptoms.
Another commonly reported concern is that patients will not comply with dietary prescriptions [15].
While not all patients are suited to follow a LPD, most of them will adhere and comply with the treatment
when given adequate information on its rationale and instructed about food choices. Implementation
of shared decision-making, careful selection of the patients, availability of resources, and dedicated
interdisciplinary teams (including nephrologists, dieticians, nurses, psychologists, and social workers)
may facilitate adherence [16,17].
In CKD clinics, medical nutrition therapy (MNT) has been often considered as an ancillary lifestyle
intervention whose role is somehow subordinated to pharmacological treatment. In this review,
we would like to challenge this view and argue that MNT should be a cornerstone of the management
of CKD as well as of other chronic diseases. The American Heart Association recently claimed diet
quality to be the main predictor of death in the U.S. and that it should not be treated as anything less
than a vital sign [18].
By definition, a medication is “something that treats, prevents, or alleviates the symptoms of
disease” (https://www.thefreedictionary.com/medication); LPDs fulfill these criteria, with expected
favorable effects, contraindications, and adverse reactions. We believe in the impact of MNT on the
patient’s health and consider the implementation of LPD diets equal to the prescription of a medication.
Here, we discuss the importance of LPDs in CKD through the lens of a pharmacological
approach, and summarize the mechanisms of LPDs’ action, indications, contra-indications, dosages,
unwanted side effects, and special warnings. Acknowledging this concept is essential to ensure the
success and safety of a dietary plan within a tailored and patient-centered MNT.
2. What Is a Low Protein Diet
A LPD is defined as a diet providing less than 0.8 g/kg b.w. (body weight)/day of protein [Food and
Nutrition Board of the Institute of Medicine, National Academy of Science]. This threshold of intake is
recommended by the U.S. Recommended Dietary Allowances (RDA) (https://www.ncbi.nlm.nih.gov/
books/NBK234926/). RDAs are established from the minimum daily requirement covering the daily
needs of 95% of the population; in the case of proteins, this is set as 0.46 g/kg b.w./day. This threshold
is calculated by considering the intake of proteins of “high biological value”. The proteins at high
biological value are those that provide all the essential amino acids, and traditionally this term has
been considered as synonymous of animal proteins. From such minimum daily requirement, the RDA
added 30% in acknowledgement of the consumption of proteins of high and low biological value
within the diet, and another 30% to ensure safety. This is how the RDA of 0.77 g of protein/kg b.w./day
was reached, and then approximated to 0.8 g/kgb.w./day.
The primary sources of animal proteins include beef, poultry, fish, eggs, milk and dairy products,
and others. The list also contains processed food, like processed meats (sausages, ham, smoked turkey,
bologna, and some types of cheese).
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When prescribing a LPD, the intake of such foods tends to be discouraged, and thus LPDs are
generally compatible with the concept of plant-based diets, as they result in a higher consumption of
plant-derived foods, namely legumes, vegetables, cereals, and tubers [19].
Because of other healthy nutrients present in plants, this switch may result in additional benefits,
beyond protein restriction. Conversely, reducing the intake of animal-derived foods and of ultraprocessed
foods (especially when added with phosphate containing additives) [20], reduces unhealthy nutrients,
such saturated fat, sodium, phosphate, and potassium.
LPDs must ensure adequate energy intake, which is estimated by the 2020 KDOQI guidelines [7]
as 25–35 kcal per kg of ideal body weight per day. This figure, which is lower than the previous
recommendations of 30–35 kcal/kg b.w./day [21], is the result of acknowledging both the older age
of patients with CKD and the fact that the correction of anemia and acidosis is nowadays more
effective than at the time in which previous thresholds were set, at least partly counterbalancing the
hypercatabolic state of advanced CKD.
The way to calculate the energy and protein needs should be based on clinical judgment, as advised
by the NKF-KDOQI Clinical Practical Nutrition Guideline [7]. If the patient’s body mass index is
normal or overweight, the actual body weight is used to calculate energy and protein needs.
If the patient is obese or underweight, simply using a normative table of ideal body weight may
not be enough. The clinical assessment includes evaluation of the body weight that the patient has
maintained during adult life, the body weight that the patient considers adequate, and the body weight
that minimizes the risk for developing complications from obesity or the risk for PEW. Therefore,
normative body weight tables, respecting country, or ethnicity whenever possible, should not be the
only parameter to calculate energy and protein needs.
3. Types and Dosages of Low Protein Diets
The requisite of the low-protein regimes is to ensure an adequate energy intake (25–35 kcal/kg b.w./day) [7].
Although many LPDs are possible in clinical practice, the following combinations (Table 1) are the
most frequently reported in the medical literature, at least in western countries [22,23].
Table 1. Main types and dosages of low protein regimens.
Type of Diet Protein Restriction (g/kg ofbody weight per day) Main Features
Conventional low protein diet 0.55–0.60 g/kg b.w./day;mixed protein
This regimen is a very popular choice in Italy, where
protein-free food is provided free of charge to CKD
patients. Protein-free pasta, bread, and other
carbohydrates substitute the usual bread, pasta, or rice.
Vegan low protein diet 0.6–0.8 g/kg b.w./day;vegetable protein
Protein intake in vegan diets is on the average
0.7–0.9 g/kg/day; due to the different bioavailability,







A simplified prescription is based upon food to be
avoided (animal origin) and preferred (vegetable origin)
food. Animal-derived food is allowed only in
unrestricted meals. Supplementation is tailored upon
nutritional status and clinical situation (1 pill every 8 to
10 kg of ideal body weight)





This diet may be upon food to be avoided (animal origin)
and preferred (vegetable origin) food. Animal-derived
food is negotiated with the patient in few “free meals”
(usually no more than 1 per week). Supplementation of
ketoacids is higher (1 pill every 5 kg of ideal body
weight). Carbohydrates are mainly from protein-free
products in countries where this is available, as in Italy.
Tailored solutions Usually 0.6–0.8 g/kg b.w./day,vegetable or mixed
These solutions employ different combinations of
protein-free food, vegan diets. and supplementation to
encounter patient’s taste and metabolic needs.
CKD = Chronic Kidney Disease.
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3.1. Conventional Low Protein Diet
The conventional LPD contains 0.6 g/kg b.w./day of proteins, of which at least 50% are of
high biological value, such as egg, fish, and meat [24]. Besides ensuring that energy requirements
are met, these diets should provide carbohydrates (contributing to 55–60% of the total energy
intake), and lipids (contributing to 30–35% of the total energy intake). By limiting protein-rich
foods (including dairy products and processed foods), this diet is also usually low in phosphate
(600–800 mg/day), sodium (2–3 g/day), and calcium. By avoiding the intake of ultra-processed food
(i.e., industrial ready-to-eat food, like ham, sausages, some types of cheese, smoked turkey, etc.) and
increasing the intake of whole or minimally processed foods (fresh fruits and vegetables, cereals.
And grains), this diet has the additive benefits described earlier.
Combining a low protein intake with a normal-to-high energy intake may be easier with the
use of protein-free products that may represent a main energy source [25]. These products include
pasta, noodles, bread, biscuits, flour, and precooked soups and desserts. This diet choice is particularly
frequent in Italy, where these foods are reimbursed by the national health service [24])
3.2. Vegan Low Protein Diet
The vegan LPD provides 0.6 to 0.7 g/kg b.w./day. It is an option where protein-free products
are not available or when the patient refuses to use them [24]. The crucial point is to cover the
needs for essential amino acids in the presence of a protein intake lower than the RDA. To reach this
goal, the diet is based upon combinations of cereals and legumes to complement the essential amino
acids [26]. In fact, overall cereals and legumes are respectively poor in lysine and methionine; however,
since cereals are rich in methionine whereas lysine is well represented in legumes, mixtures of cereals
and legumes are complementary and nutritionally adequate.
3.3. Supplemented Plant-Based Diet
The supplemented plant-based LPD supplies 0.6 g/kg b.w./day of unselected mainly plant-derived
proteins, supplemented with essential amino acids and/or ketoacids (1 tablet every 8–10 kg of body
weight; the composition is available in the supplemental material). This dietary regimen includes only
plant-derived foods (fruits, vegetables, sugars, starches such as pasta and bread, couscous, polenta,
and legumes) supplemented with amino acids and ketoacids. The supplementation allows choosing
any type of plant-derived food without the need to integrate different types of vegetable proteins
(grains and legumes at each meal). The supplement intake depends on the body weight, type of
diet, and nutritional status. The tablets should preferentially be taken during the meal. One to three
unrestricted meals per week are usually allowed, to reduce diet tiredness and minimize the risk for
nutritional deficits [27].
3.4. Very Low Protein Diet
The very low protein diet (VLPD) contains about 0.3 g/kg/day of proteins, supplemented with a
mixture of essential amino acids and ketoacids (1 tablet for every 5 kg of body weight). This dietary
regimen is usually achieved with a vegan diet. The target is usually limited to selected patients with
stage 5 CKD and with high dietary compliance. It is generally implemented when conventional or
vegan LPDs are not sufficient to maintain the metabolic homeostasis and the start of dialysis is not
advisable, or not chosen by the patient [28–30].
4. Mechanism of Action of Low Protein Diets
The LPDs work, because they reduce the production of protein-derived waste products,
the retention of protein-derived toxins and fixed acids, lower single nephron glomerular hyperfiltration
and proteinuria, and reduce dietary phosphate load.
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LPDs reduce the amount of protein-derived waste products and fixed acids, contributing to kidney
protection and to the attenuation of metabolic abnormalities [1,2]. At each level of kidney function,
a lower generation of protein–waste products lead to lower blood levels of uremic toxins, phosphate,
and fixed acids.
In the kidney, a lower dietary protein load results in a reduction of single nephron hyperfiltration
and glomerular hypertension, as well as trans-glomerular protein traffic [31].
Protein sources (i.e., plant or animal protein) may be relevant, but the evidence in this regard is
scant. Early studies suggested that the favorable changes in glomerular hemodynamics may be more
marked with plant-derived rather than animal-derived proteins [32].
The increased intake of complex carbohydrates and fibers contributes to establishing a favorable
balance in the gut microbiota, favoring beneficial bacterial species with predominant saccharolytic
metabolism (Figure 1) [33,34]. These micro-organisms ferment complex carbohydrates and fibers,
producing short-chain fatty acids, such as acetate, butyrate, and propionate that serve as fuels for
the intestinal epithelium and may have positive immune-modulatory effects. The reduction of urea
limits its diffusion into the intestinal lumen, counteracting the vicious cycle of changes in intestinal
microbiota, increase in intestinal permeability, and passage of bacterial toxins in the circulation [35].
Figure 1. Renal nutritional management in chronic kidney disease (CKD) patients, on stages 3 to 5 not on
dialysis: shifting from a high protein diet to a low protein and/or plant-based diet. CKD-MBD = Chronic
kidney disease mineral and bone disorders.
5. Indications of Low Protein Diets
The main indications of LPDs are to delay the start of renal replacement therapy, the prevention
and treatment of metabolic and electrolyte abnormalities, the prevention of protein–energy wasting,
and the improvement of patient quality of life by reducing uremic symptoms, an additive contribution
to the management of proteinuria, hypertension, and dyslipidemia (Figure 1).
Delay of the start of renal replacement therapy is a primary objective of LPDs. Besides the obvious
advantages in terms of quality of life and cost of treatment, delaying dialysis may actually increase
life expectancy, as recently underlined by the KDIGO guidelines [36]. LPDs may delay the start of
dialysis in two ways: in the long run, the reduction of single-nephron hyperfiltration and proteinuria
may slow the rate of decline of the residual kidney function; in the short run, LPDs improve the
metabolic balance, reducing uremic symptoms and maintaining the nutritional balance, thus allowing
to postpone dialysis, even if at stable glomerular filtration rate (GFR) [2,37]. Table 2 summarizes
the main randomized controlled trials (RCT) investigating the role of protein restricted regimens on
retarding the deterioration of renal function in CKD patients. In order to build this table, RCTs including
at least 200 patients and with follow-up of at least 6 months were selected. Although the main findings
of these studies separately do not support the role of low-protein regimens on retarding the progression
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of the disease, a recent meta-analysis including 16 studies showed that when pooling these studies
together with others with smaller sample sizes together, the risk of progression to End Stage Kidney
Disease(ESKD) was lower in patients receiving low protein regimens [38].
LPDs contribute to the prevention and control of various metabolic and electrolyte abnormalities,
signs, and symptoms of CKD (Figure 1). These benefits are not necessarily mediated by the effect
of protein restriction, but by the reduction of electrolytes and acids that usually accompany animal
protein and ultraprocessed foods. By consuming more plants, LPD provide a higher intake of fibers,
bioactive components, vitamins, antioxidants, and a more alkaline diet. This may have implications
in blood pressure control and management of metabolic disturbances such as hyperphosphatemia,
hyperkalemia, metabolic acidosis, and dyslipidemia. A secondary analysis of the Modification of Diet
in Renal Disease (MDRD) study showed that a reduction of 0.2 g/kg b.w./day of protein per year was
associated with lower serum concentrations of urea and phosphate, and higher levels of bicarbonate in
patients with CKD stages 3–5, randomized to LPD or very low protein diet (VLPD) + keto analogues [39].
Cianciaruso et al. showed that patients following a LPD (0.6 g/kg b.w./day of protein) had lower
serum urea nitrogen and needed lower bicarbonate supplements, phosphate binders, allopurinol,
and diuretics [40]. The effect of LPDs in maintaining bicarbonate levels and lowering serum urea is
consistent, and confirmed by a recent meta-analysis of 16 randomized controlled trials [38].
Table 2. Summary of the randomized controlled clinical trials, including more than 200 patients with
follow-up > 6 months, investigating the role of protein restricted diets in patients with chronic kidney
disease of stages 3 to 5 (not on dialysis).









228 pts (15 to 73 years old)
GFR 30 to
60 mL/min/1.73 m2
LPD 0.6 g/kg/day vs. UPD
GFR ≤ 30 mL/min/1.73 m2
LPD: 0.6 g/kg/day vs. UPD.
2-year follow-up.
The LPD groups showed
lower decrease in serum
Creatinine over time,
whereas the UPD groups
showed no changes.
The LPD had a lower
serum urea during the
study when compared to
the UPD group.
No changes in body
weight and serum
albumin were observed
during the study in the











456 pts (18–65 years old)
GFR < 60 mL/min/1.73 m2
LPD: 0.6 g/kg/day vs.
UPD: 1.0 g/kg/day.
2-year follow-up.
Renal survival was a
lithe bit higher in the
LPD group vs.
UPD (p = 0.06).




Low adherence to the
prescribed protein intake
in the LPD group.
No changes in body
weight were observed
during the study in the
LPD and UPD groups.








GFR rate of decline.





LPD: 0.6 g/kg/day vs.
UPD: 1.3 g/kg/day.
2.2-year follow-up
No differences in the rate




Low adherence to the
protein prescribed in
LPD and UPD groups.
Nutritional status was
maintained thru the
study in the LPD,
UPD and VLPD groups.













BP control level: usual vs.
low LPD: 0.6 g/kg/day vs.




No differences in the





a trend to slower GFR
decline was observed in
the VLPD vs. the LPD
group (p = 0.07).
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Table 2. Cont.
Author, Year Aim and Outcome Sample Characteristics Main Findings Comments
Cianciaruso et al.,
2008 [40]




392 patients (Age > 18 years)
GRF ≤ 30 mL/min/1.73 m2
LPD: 0.6 g/kg/day vs. UPD:
0.8 g/kg/day.
6 to 18 months follow-up.
No difference in serum
urea between LPD and
UPD group, but serum
urea was lower in
patients adherent to LPD.
The need for medications
was lower in the LPD vs
UPD group.
Nutritional status was











207 pts median age 54 years
eGFR < 30 mL/min/1.73 m2
and proteinuria < 1 g/day.
LPD (0.6 g/kg/day) vs.




VLPD plus EAA and KA
was more effective than
LDP in delaying the start
of dialysis or avoiding
50% loss of GFR,
especially n patients
with GFR < 20 mL/min.
Compliance to diet was








LPD: Low protein diet; UPD: Usual protein diet; VLPD: Very low protein diet; GFR: Glomerular filtration rate;
eGFR: Estimated glomerular filtration rate; BP: Blood pressure; CKD: chronic kidney disease; EAA: essential amino
acids, KA: ketoacids.
Furthermore, in patients with advanced CKD not on dialysis, a higher fiber to protein ratio was
associated with lower concentration of uremic toxins derived from the gut microbiota (p-cresyl sulfate
and indoxyl-sulfate), suggesting the selection of a healthier microbiota [45,46].
Almost paradoxically, LPDs can contribute to the prevention of PEW. The pathogenesis of PEW in
CKD is multifactorial [8,9], but usually combines hypercatabolism and insufficient food intake. Loss of
appetite is linked to the accumulation of nitrogen waste products, altered concentration of appetite
regulators (such as ghrelin or cholecystokinine), dysbiosis, and local alterations such as periodontitis,
and gastritis. Inadequate intake can also result from excessive restrictions that may leave the patient
with few options to allow a healthy diet. Hypercatabolism is driven by a combination between chronic
pro-inflammatory state, insulin resistance, metabolic acidosis and secondary hyperparathyroidism.
These conditions result into a loss of muscle mass and fat stores [47].
By reducing production and retention of uremic toxins, low protein diet have the potential of
reducing waste-products contributing to anorexia; furthermore, plant-derived foods contribute to
reducing the net acid production, favoring the acid-base control [48].
Low protein intake can reduce proteinuria both of nephrotic and non-nephrotic range, and this
effect is additive to the inhibition of the renin–angiotensin–aldosterone system (RAASi) [49,50].
The additive effect is explained by the different site of action: Reducing protein intake, especially of
animal origin, reduces the afferent arteriole dilatation, whereas the RAASi lowers the resistance
of the efferent arteriole. Both modifications reduce intraglomerular pressure and protein leakage.
These favorable changes are also reported in iso-nitrogen load of plant-derived proteins.
The reduced sodium intake often associated with LPDs contributes to lowering arterial blood
pressure [51]. These effects are additive to drug effects and reinforce the nephro-protection.
6. Contraindications to LPDs
Some contraindications to low protein diets exist, and they may be considered as absolute or
relative (Table 3, Figure 2). As absolute contraindications may be assumed as acute hypercatabolic
conditions, protein energy wasting, anorexia nervosa and eating disorders, and end of life care.
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Table 3. Low protein diets as a medication.
A. Types and Dosages of Low Protein Diet
- Conventional LPD, supplying 0.55 to 0.60 g/kg b.w./day of mixed proteins, at least 50% of high biological value.
- Vegan LPD, supplying 0.6–0.7 g/kg b.w./day of plant origin proteins using a special combination of cereal and legumes, and/or soy.
- Very low protein diet to patients with CKD and without diabetes: 0.28 to 0.43 g/kg b.w./day with additional keto acid/amino acids
to meet protein requirement of 0.55 to 0.60 g/kg b.w./day, usually 1 tablet every 5 kg b.w.
- Mostly vegetarian diets supplying 0.7–0.8 g/kg b.w.d of unselected proteins, supplemented or not with essential amino acids and
ketoacids (usually 1 tablet every 10 kg b.w).
B. Mechanisms of Action of Low Protein Diet
- Reduced production of protein-derived waste products
- Reduced retention of protein-derived toxins and fixed acids
- Reduced phosphate load, with lesser stimulation of parathyroid hormone production
- Reduced single-nephron glomerular hyperfiltration
- Reduced urine protein excretion
C. Indications to a Low-Protein Diet
- Prevention and treatment of metabolic and electrolyte abnormalities, signs and symptoms of chronic renal insufficiency
- Prevention of protein-energy wasting
- Delay the start of renal replacement therapy
- Management of proteinuria, hypertension, or progressing chronic kidney disease
D. Contraindications to a Low-Protein Diet
Absolute
- Protein energy wasting
- Hypercatabolic state (acute or chronic)
- Anorexia and eating disorders
- End of life care management
Relative
- Poor attitude to dietary modifications
- Psychiatric / psychological disorders
- Logistic barriers (economic, cultural, lack of support)
- Poorly controlled diabetes
- Chronic steroid treatment
- Intestinal diseases including chewing disorders
- Short life-expectancy
E. Unwanted Side Effects of LPD
- Weight loss due to reduced energy intake
- Loss of muscle mass due to inadequate protein and energy intake
- Depression, relational problems, psychological discomfort










- Very old, aged patient
- Neuromuscular disorders
- Short life expectancy
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Acute severe diseases increase protein requirements, and thus represent an absolute contraindication
to a LPD. High circulating levels of cytokines and pro-inflammatory molecules increase protein catabolism
to face the acute event. In these settings, low protein intake can blunt the stress response and enhance
the loss of lean body mass.
PEW, characterized by signs of muscle wasting, inability to spontaneously reach daily
energy/protein targets, malnutrition as assessed by subjective global assessment or other validated
scores, requires interventions aimed at restoring caloric intake, without protein restriction.
Eating disorders are usually considered absolute contraindications to low protein diets, to avoid
interference with the diet management aimed at controlling the underlying disease. Information is
scant as these patients are routinely excluded from trials and observational studies on LPDs [52].
In end of life care, starting a low protein diet is considered futile, unless aimed at symptom control
(see specific paragraph below).
As relative contraindications, we consider most of the barriers (economic, cultural, lack of support,
and so on) to LPD implementation, psychiatric disorders, poorly controlled diabetes, chronic steroid
treatment, chronic gastro-intestinal diseases, including chewing disorders and short life-expectancy.
Relative contraindications to initiate or continue a LPD include both specific diseases and
conditions that impair adherence to a diet, but that may be overcome, corrected, or removed. This latter
category includes socio-economic issues, depression, psychological distress, chewing disorders, lack of
motivation or of family and social support. To overcome these barriers, dietary prescriptions should
be carefully monitored and, when needed, mitigated in particular during periods of clinical or
physiological distress.J. Clin. Med. 2020, 9, x FOR PEER REVIEW 9 of 19 
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In patients with psychiatric disorders, including depression, a restrictive diet may increase distress;
in these cases, atten ion should also be paid to th devel pment of c mpulsive obsessiv behavior,
with the risk of over-restrictive attitudes, ultimately inducing malnutrition.
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With regard to specific diseases or treatment frequently associated with CKD, chronic steroid
treatment, and poorly controlled diabetes are often cited. High-dose, or long-term corticosteroid
therapy increases protein catabolism, and induce sarcopenia; while full-blown steroid induced Cushing
syndrome is becoming rare, indolent pictures are frequent and represent one of the reasons why LPDs
are seldom prescribed in kidney transplant patients. Poor glycemic control in diabetic patients increases
protein requirements and prevents adaptation of nitrogen metabolism to low protein intake [53,54].
The same is the case for severe metabolic acidosis.
Sarcopenic obesity, is not uncommon in advanced CKD [55], and there are no clear indications on
how to combine energy reduction (given that obesity is a risk factor for CKD progression with protein
restriction [56]. Chronic gastro-intestinal diseases and chewing disorders require particular attention,
with the need to carefully advice on food choices.
Finally, short-life expectancy may also be considered a relative contraindication to starting or
maintaining protein restriction, since changing dietary habits or restricting diet could be deranging
and futile.
7. Unwanted Side Effects of LPD
Weight loss due to inadequate energy intake, Loss of muscle mass due to inadequate protein
and energy intake. Depression, relational problems, psychological discomfort, overdosing(excessive
protein restriction) or underdosing (ineffective protein restriction) (Table 3).
Unwanted weight loss is one of the most important concerns in patients on a LPD. Reduction of
body weight, when not attributed to reduced fluid overload, means inadequate energy intake that
is invariably associated with increased nitrogen need and prevents achieving the neutral or positive
nitrogen balance that should characterize a well conducted LPD [53,57]. Loss of muscle mass may
occur both when protein intake is adequate, but energy intake is insufficient and when the intake of
protein and amino acid is inadequate. Importantly, a sedentary lifestyle is strictly associated with
sarcopenia, and may enhance the loss of lean body mass. Long term adherence may be reduced by
“diet tiredness”, associated with overzealous restrictions, use of poor tasty products, monotony, loss of
appetite, potentially resulting in weight loss or in loss of focus, and reduced compliance.
Psychological discomfort and depression may occur as a result of the many hurdles CKD patients
face in the course of their disease. Older patients may suffer from lack of appetite, sometimes aggravated
by social isolation; chewing problems may reduce food choices and food variety may be limited by
a small budget. Younger patients who work full time may need to regularly take eat meals outside
home, where food choices are not always easy, or feel socially limited in their leisure time. In this
regard, understanding the importance of LPD and knowledge of food choices, level of health literacy
and coping capacity are important determinants of adherence [58]. Individualized dietary programs,
intensive educational interventions, and regular counseling are needed to promote adherence to LPD.
Over-dosing may occur. Excessive protein restriction (possibly leading to insufficient energy
intake) carries a high risk of PEW and of various vitamin and micronutrient deficits.
Under-dosing may also occur, linked to lack of dietary adherence, which obviously limits or
impairs the efficacy of LPDs. A stepwise approach to protein restriction may help reaching targets and
gaining confidence in the dietary modification (see implementation strategies).
In the presence of unwanted effects, the decision to continue the LPD depends on the severity
and potential reversibility of the side effect. Shared decision-making and careful multidisciplinary
follow-up are very important in these contexts.
8. Dietary Supplements
In some patients, nutritional supplements may be required to ensure the nutritional safety of a
LPD and are mandatory in the case of a VLPD [59]. They include a mixture of essential amino acids
and ketoanalogues, calcium, vitamins and iron preparations.
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The most widely used supplements are a mixture of calcium salts of essential amino acids and
keto acids, currently available world-wide, with small differences in composition [59,60]. The total
nitrogen content per tablet is 36 mg, and the calcium content is 50 mg (1.25 mmol). In Italy the product
of choice is identical, except for the absence of tryptophan [61].
Regular monitoring of vitamins, calcium and iron is required to target further supplementations.
By reducing the intake of phosphate-rich foods, calcium intake is usually decreased,
and supplementation with 500–1000 mg of calcium may be needed.
Low iron stores may be due to the lower bioavailability of iron from plant-derived foods, and oral
supplementation may also be needed.
Vitamin B12 supplementation is usually necessary for patients on a vegan diet for a long period,
while it is rarely necessary when a vegan diet is alternated to conventional LPDs that provide a daily
amount of meat or fish.
9. Special Warnings
9.1. Nephrotic Syndrome
Up to the 1980s, nephrotic syndrome was considered a contraindication for a LPD. Afterwards,
experimental and human studies showed that reducing dietary protein load decreased urinary protein
excretion [48], and this effect was synergic with RAASi [50]. The anti-proteinuric effect of LPDs
was associated with an amelioration of albumin homeostasis and an increase in plasma albumin
levels [62,63].
The additive effect of LPD and RAASi is explained by the combination of afferent arteriole
vasoconstriction, induced by LPDs and post-glomerular vasodilatation, induced by angiotensin-
converting-enzyme inhibitors [49,50]. The effect may be more marked in plant-based diets [64,65].
9.2. Diabetes
Historically, LPDs were contraindicated in diabetic patients with diabetes, and, on the contrary
protein intake was increased to reduce carbohydrate load; indeed, early studies suggested a risk of
malnutrition when implementing a LPD in these patients [66–69]. However, data in the literature
are conflicting and this contraindication may no more be true. At present, worldwide most of the
CKD diabetic patients are affected by type 2 diabetes and, at least in Europe, intensely proteinuric
nephropathies leave the place to vascular nephropathies [70].
A recent consensus [68] and the 2020 update of the KDOQI clinical practice guidelines for nutrition
in CKD suggest caution in reducing protein intake in patients with diabetes, setting a higher target
of protein restriction (0.8 g/kg b.w./day) [7]. These indications are also shared by the International
Society of Renal Nutrition and Metabolism [71]. Of note, this target is set to ideal body weight,
which may correspond to consistently lower figures when referred to real body weight in type
2 diabetes patients [7]. It is also worth mentioning that low-carbohydrate diets with high protein
content are increasingly proposed for weight reduction. A randomized trial has been advocated to
assess whether low-carbohydrate diets are safe in diabetic patients with CKD [72].
9.3. Obesity
Obesity is an independent risk factor for CKD and cardiovascular diseases. It contributes to
physical limitations and decline of functional status and is associated with poor quality of life and
higher morbidity and mortality in the pre-dialysis phase.
Although evidence exists about the survival advantage of obesity in dialysis patients [73],
reaching a normal or near-normal body mass index is often required for being wait-listed for kidney
transplantation. Energy restriction increases protein requirements, so that a low protein diet may not
be able to maintain an adequate nitrogen balance, thus increasing the risk of PEW.
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Thus, energy restriction is potentially conflicting with a low-protein diet and, as a consequence,
the two approaches are rarely combined. Priorities should be set on a case by case basis [24]. When a
low-protein diet is indicated in an overweight or obese patient, protein restriction should probably be
prescribed with an energy intake covering at least the daily requirements per ideal body weight [5].
9.4. Very Old Age
The NKF/KDOQI guideline in nutrition and CKD makes no specific recommendation for the
elderly but suggests to carefully monitor energy intake in this group of patients in which food
intake is often reduced, to a variety of reasons. Protein anabolism is reduced in older individuals
and geriatric societies usually advice increasing protein intake of 1.0 to 1.2 g/kg b.w./day in elderly
individuals, thus particular attention should be placed in protein restriction in elderly CKD patients. [74].
Furthermore, elderly patients are usually considered resistant to change their dietary habits.
However, due to the high mortality and morbidity of elderly patients on dialysis, delaying or
even avoiding it dialysis of particular importance.
Brunori et al. in one of the few randomized controlled trials available in elderly patients,
showed that a supplemented VLPD was able to delay by about one year the need of dialysis in
elderly patients with no consequence on morbidity and mortality [28,75]. While very old patients
(usually defined as over 80 years of age) are seldom included in RCTs, good results, at least in terms
of safety, are reported in observational cohort studies [76]. A careful evaluation of dietary habits,
functional and cognitive status, and regular monitoring of the nutritional status may allow extending
the indications to this wide subset of the CKD population, selecting patients who can benefit from
LPDs and adapting dietary recommendations to their needs [76,77].
9.5. Pregnancy
Pregnancy in CKD is a condition in which the advantages of the diet for the mother have to be
carefully balanced with the theoretical risk for intrauterine growth restriction [78–81].
While most of the experiences come from a single referral center, available data suggest that
moderately protein restricted, plant-based diets, whenever possible supplemented with amino acids
and their keto-analogues, may allow stabilization of kidney function in pregnancy [78,81]. These diets
are associated with an almost paradoxical improvement in intrauterine growth, and a significant
reduction of a combined outcome encompassing early preterm delivery (<28 gestational weeks) and
birth weight < 10 percentile per gestational age [81].
Protein restriction reported in these experiences is mild, targeting 0.6 g /kg b.w./day in the first
half of pregnancy and 0.8 in the second half, accounting for the usual increase in energy and protein
requirements during the last phases of gestation. The supplementation is usually increased from
1 tablet every 10 kg in the first 20 weeks to 1 tablet every 5–8 kg in the second half of the pregnancy.
The same approach, aimed at blunting pregnancy-related hyperfiltration and the consequent increase
in proteinuria, has been employed in patients with relevant proteinuria but preserved GFR at start of
pregnancy [81,82].
Strict surveillance, and multidisciplinary care is needed to combine the multiple requirements of
pregnancy with the prescribed protein intake.
9.6. Neuromuscular Disorders
Patients with spinal cord injury are at risk of developing metabolic diseases, including cardiovascular
diseases, dyslipidemia, diabetes, and CKD. The latter is not only linked to the higher cardiovascular risk
but often results from chronic urinary infections, bladder dysfunction, and nephrolithiasis. Patients with
spinal cord injuries tend to increase fat body mass, reducing lean body mass, due to the lack of
physical activity. In the absence of evidence regarding the efficacy of LPDs in this particular population,
an individualized energy restriction with a normalized (0.8 g/kg b.w./day) protein intake may represent a
feasible dietary option [83–85].
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9.7. Short Life Expectancy
The concept of short life expectancy is complex and the term ambiguous, since it has been used
for indicating periods of days-months (often less than 3 months), to longer periods, in particular when
the term short is used with respect to the overall population.
Life expectancy of less than 3 months is considered a relative contraindication to the start of a
classic nutritional approach, mainly based upon protein restriction, in patients with CKD stage 3–4,
since death is expected before CKD progression, and changing dietary habits could be deranging and
is expected to be futile.
When life expectancy is severely reduced but expected to be between 3 to 12 months,
nutritional management may, on the contrary, have a fundamental role, in particular in cases with rapidly
progressive CKD. In fragile, stage 4 and 5 CKD patients, the need of dialysis can be avoided, considering not
only the fact that dialysis usually impairs quality of life more than a low-protein diet but also the excess
mortality at dialysis start. Similar considerations may apply to the “palliative” care of patients with
advanced CKD.
10. Implementation and Monitoring
A common strategy for reaching the target energy and protein intake has not been agreed upon,
and each team should work according to socio-cultural habits and personal/center experience [86].
The following points are however commonly highlighted: assessment, stepwise approach, follow up,
and personalization (Figure 2).
Assessment of the baseline dietary habits is the first very important step, as well as assessment of
body composition and functional status. At the beginning of treatment, especially when the current
protein intake is high, it is reasonable to progressively reduce the protein intake by subsequent steps,
indicatively of 0.2 g/kg b.w./day trying to normalize protein intake as a first goal (0.8 g/kg b.w./day) [39,76].
The target value can then be gradually reached by progressive adaptation of protein intake,
based on the metabolic and clinical homeostasis and with a shared decision-making process involving
the patient and the caregivers. Variety of the food choices may support adherence in the long-term.
Different strategies have been suggested, including unrestricted meals, or alternating vegan diet and
conventional low-protein diet [8,27,87–89].
Nutritional monitoring of patients on low protein diets aims to verify the adherence to dietary
prescription and to early detect PEW, is any. The assessment of adherence is essentially a control of the
stability of CKD: in this regard, we suggest monitoring of serum urea, phosphorus, parathormone (PTH),
hemoglobin, bicarbonate, proteinuria and residual renal function. Expected effects of LPDs are the
initial reduction and subsequent stabilization of serum urea, phosphate, PTH, stabilization of eGFR,
and increase or stabilization of serum bicarbonate and albumin. Evaluation of 24-h urine excretion of
sodium, phosphate, and urea allows estimating the respective dietary intakes.
As indicated also in the recent KDOQI guidelines, body composition should be controlled
to timely identify PEW: body weight, subjective global assessment, malnutrition-inflammation
score, serum albumin, serum cholesterol, and body composition analysis are the main assessments.
Monitoring of diet diary and quality of life is also recommended [3]. Performance measures such as
gait-speed or handgrip strength, are increasingly recommended.
Information and education are mainstays to facilitate adherence [15]. The form of the educational
sessions is culture-sensitive and may include interactive presentations engaging the professional figures
involved in the clinical management of CKD, whose aim is direct patient involvement in diagnostic
and therapeutic decision-making processes [90–92].
11. Conclusions
MNT should not be considered only a lifestyle option in CKD, but instead a core element in
its management. LPDs are effective therapies to delay the start of dialysis and have additional
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benefits beyond protein restriction by promoting better dietary quality. The degree of evidence
recently identified for this treatment (1A) is similar to that of other cornerstone therapies like RAASi
(graded 1B by KDIGO) [7], and as such a LPD should be prescribed. As with all medications, LPDs have
indications and contra-indications, and require considering different approaches and evaluating the
risk of unwanted side effects (Table 3, Figure 2).
Successful implementation requires motivation and close interaction between patients and
members of an interdisciplinary team including physicians, nurses, dietitians, and social workers.
In our experience, this kind of implementation of LPD can give more chances of efficacy and safety.
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